Abstract
Killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering apoptosis, the cells intrinsic death program. Accordingly, defects in apoptosis pathways can result in cancer resistance to current treatment approaches. Understanding the molecular mechanisms that regulate cell death programs including apoptosis, and how resistant forms of cancer evade apoptotic events, may provide novel opportunities for cancer drug development.
Keywords: apoptosis, cancer, mitochondria, cancer therapy, resistance
Current Cancer Drug Targets
Title: Targeting Apoptosis Pathways in Cancer Therapy
Volume: 4 Issue: 7
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: apoptosis, cancer, mitochondria, cancer therapy, resistance
Abstract: Killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering apoptosis, the cells intrinsic death program. Accordingly, defects in apoptosis pathways can result in cancer resistance to current treatment approaches. Understanding the molecular mechanisms that regulate cell death programs including apoptosis, and how resistant forms of cancer evade apoptotic events, may provide novel opportunities for cancer drug development.
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Targeting Apoptosis Pathways in Cancer Therapy, Current Cancer Drug Targets 2004; 4(7) . https://dx.doi.org/10.2174/1568009043332763
DOI https://dx.doi.org/10.2174/1568009043332763 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Systems Cytogenomics: Are We Ready Yet?
Current Genomics Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Withdrawal Notice: Nano Sensors: Designing and Fabrication, Applications for Flexible Devices and Future Perspectives
Current Nanoscience Preparation of Doughnut-like Nanocomposite Colloidal Crystal Particles with Enhanced Light Diffraction Using Drying Self-assembly Method
Current Nanoscience Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Current Radiopharmaceuticals Editorial [Hot Topic: Bacterial Vectors for Gene & Cell Therapy (Guest Editors: Mark Tangney & Cormac G.M. Gahan)]
Current Gene Therapy Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets A Review of the Primer Approximation Multiplex PCR (PAMP) Technique for Detecting Large Scale Cancer Genomic Lesions
Current Bioinformatics Epigenetics in Brain Tumors: HDACs Take Center Stage
Current Neuropharmacology Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development
Current Drug Targets Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment
Current Pharmaceutical Biotechnology Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Synthesis and Biological Evaluation of Triazole-Vanillin Molecular Hybrids as Anti-Cancer Agents
Current Bioactive Compounds [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy
Central Nervous System Agents in Medicinal Chemistry